Expiry of Share Options

RNS Number : 3089Y

Destiny Pharma PLC

05 September 2022

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Expiry of share options

Brighton, United Kingdom - 5 September 2022 - Destiny Pharma (AIM: DEST), a clinical stage  biotechnology company focused on the development of novel products to prevent  life threatening infections, announces that 602,000 options ("Options") over ordinary shares of 1 pence in the Company have expired under the Company's EMI Scheme 2000, of which 406,500 Options relate to Dr William Love, Chief Scientific Officer.

Following the expiry of the Options, a total of 8,875,230 options remain outstanding in the Company with Dr Love holding options over 916,236 ordinary shares representing 1.25% of ordinary shares in the Company.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

Optimum Strategic Communications

Mary Clark / Manel Mateus / Eleanor Cooper

[phone]

[e-mail]  

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

Stern IR

Lilian Stern / Janhavi Mohite

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV™, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com

 

END

 

 

DSHUVAORUOUKRAR